When did AMGN go public?
Amgen Inc., one of the world's pioneering independent biotechnology corporations, officially completed its initial public offering on June 17, 1983. The company began trading its common stock on the NASDAQ exchange under the ticker symbol AMGN, securing vital early-stage capital market funding that enabled it to research, develop, and commercialize breakthrough recombinant DNA therapeutics and oncology medicines.
Related FAQs
Amgen is a global biotechnology pioneer widely known for developing and commercializing groundbreaking biologic therapies that address serious, life-threatening illnesses across multiple therapeutic areas.
Legendary Bollywood actor Amitabh Bachchan maintained a long-standing, high-profile professional relationship with Kalyan Jewellers as their primary global brand ambassador.
Amgen has faced multiple corporate and regulatory controversies over the years, spanning complex patent infringement lawsuits regarding biologic drug manufacturing, pricing scrutiny from government healthcare committees concerning high-cost therapeut...
Amgen stock maintains a promising future outlook driven by its robust biotechnology pipeline, innovative biologic therapeutics, and expanding portfolio in oncology, cardiovascular disease, and inflammation.
Amgen, one of the world's largest independent biotechnology companies, maintains its global corporate headquarters in Thousand Oaks, California, United States.
Amgen Inc. (AMGN) is a premier biotechnology heavyweight offering a compelling mix of defensive stability, robust research pipelines, and reliable dividend income for long-term investors.
Wall Street analyst consensus typically categorizes Amgen as a hold or moderate buy rather than an overwhelming strong buy.
Amgen operates uniquely as a pioneer that bridges both categories, functioning as one of the world's largest independent biotechnology enterprises while possessing the massive scale, global commercial infrastructure, and extensive manufacturing capac...
Amgen recently reported strong financial results for the second quarter, beating Wall Street earnings and revenue expectations while crossing the ten-billion-dollar quarterly revenue threshold for the first time.
Amgen has implemented targeted workforce reduction measures as part of ongoing post-acquisition integration efforts and strategic operational realignments designed to streamline research and development activities.
Amgen Inc., traded under the ticker symbol AMGN, is classified as a large-cap biotechnology stock operating within the healthcare sector.
Vice presidents managing commercial banking portfolios, risk assessment divisions, retail financial operations, or wealth management at Bank of Montreal (BMO) earn professional compensation packages reflecting major Canadian and North American bankin...
Assessing Amgen as a long-term equity investment involves analyzing secular growth trends in biopharmaceutical drug development, an extensive pipeline of innovative therapeutics, and a stellar history of dividend growth.
Amgen's product portfolio is anchored by several blockbuster medications, with Prolia and Xgeva (denosumab) for bone health and osteoporosis leading revenue generation, bringing in billions of dollars annually.
Ozempic is not manufactured or commercialized by Amgen; it is developed, produced, and distributed globally by the Danish multinational pharmaceutical corporation Novo Nordisk.